Chlorhexidine vs Morus Nigra Mouthwash Periodontal Trial
ClinicalTrials.gov Studies
Summary
NIH ClinicalTrials.gov has registered study NCT07540624, a randomized controlled trial evaluating the comparative efficacy of chlorhexidine gluconate (0.12%) and Morus nigra (blackberry, 5%) mouthwashes as adjuncts to non-surgical periodontal treatment. The study will enroll patients with periodontitis across three arms: scaling and root planing (SRP) alone, SRP plus chlorhexidine, and SRP plus Morus nigra mouthwash. Investigators will assess clinical periodontal parameters, gingival crevicular fluid inflammatory markers (TNF-a, IL-1b, IL-10), and subgingival plaque microbiological profiles at baseline, 1 month, and 3 months.
What changed
NIH ClinicalTrials.gov registered a new randomized controlled trial (NCT07540624) on April 20, 2026, comparing chlorhexidine and Morus nigra mouthwashes for periodontal treatment. The three-arm study will evaluate clinical, biochemical, and microbiological outcomes in patients receiving scaling and root planing with or without adjunctive mouthwash therapy.
This registry entry does not create compliance obligations for any regulated entity. Healthcare providers and clinical investigators interested in periodontal research may note the study parameters for awareness, but no action is required. The trial is informational for the research community rather than a regulatory action imposing obligations on industry or healthcare institutions.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Efficacy of Chlorhexidine and Morus Nigra Mouthwashes After Periodontal Treatment
N/A NCT07540624 Kind: NA Apr 20, 2026
Abstract
This study aims to evaluate and compare the clinical, biochemical, and microbiological effects of chlorhexidine and Morus nigra (blackberry) mouthwashes used as an adjunct to non-surgical periodontal treatment (scaling and root planing - SRP) in patients with periodontal diseases. The participants will be divided into three groups: a control group receiving only SRP, a group receiving SRP combined with chlorhexidine mouthwash, and a group receiving SRP combined with Morus nigra mouthwash. Clinical periodontal parameters, gingival crevicular fluid levels of inflammatory markers (including TNF-a, IL-1b, and IL-10), and subgingival plaque microbiological profiles (such as red complex bacteria and Fusobacterium) will be evaluated at baseline, 1 month, and 3 months after the treatment.
Conditions: Periodontitis, Periodontal Disease
Interventions: 0.12% Chlorhexidine Gluconate Mouthwash, 5% Morus Nigra Mouthwash, Scaling and Root Planing (SRP)
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.